clinical trial · NCT07134335
UBT251 Injection Phase II Clinical Study (CKD)
The United Bio-Technology (Hengqin) Co., Ltd.·phase2·recruiting·n = 180
Obesity &Amp; OverweightChronic Kidney DiseaseUBT251UBT251UBT251
brief summary
This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population
started
Sep 1, 2025
primary completion
Jul 11, 2030
completion
Jul 11, 2030
last updated
Nov 25, 2025
official title
A Phase II Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese/Overweight Chronic Kidney Disease (CKD) Population
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol